Cargando…
Reliability of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure: HM-PRO
BACKGROUND: Patients’ experience of symptoms often goes undetected during consultation in an outpatient clinic, and the use of a patient-reported outcome measure (PRO) in such a setting could be useful to aid treatment decision-making. A new PRO measure, the HM-PRO (Hematological Malignancy Specific...
Autores principales: | Goswami, Pushpendra, Oliva, Esther N., Ionova, Tatyana, Else, Roger, Kell, Jonathan, Fielding, Adele K., Jennings, Daniel M., Karakantza, Marina, Al-Ismail, Saad, Collins, Graham P., McConnell, Stewart, Langton, Catherine, Al-Obaidi, Magda J., Oblak, Metod, Salek, Sam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606444/ https://www.ncbi.nlm.nih.gov/pubmed/33192513 http://dx.doi.org/10.3389/fphar.2020.571066 |
Ejemplares similares
-
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Quality-of-life issues and symptoms reported by patients living with
haematological malignancy: a qualitative study
por: Goswami, Pushpendra, et al.
Publicado: (2020) -
Clinical Outcomes in Patients with Hematologic Malignancy (HM) and COVID-19
por: Cook, Michael Roderick, et al.
Publicado: (2020) -
P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)
por: Antoniadi, K., et al.
Publicado: (2022)